Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application
Clinical and Translational Medicine · 2026-06 · 16 (6)
DOI: 10.1002/ctm2.70707 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 01.06.2026. Verfasst von Juan Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng …. Hauptthemen laut MEDLINE: Ferroptosis, Iron, Breast Neoplasms, Adipocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Peking Union Medical College.
Abstract (Originalsprache)
Background
Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, has emerged as a potential therapeutic vulnerability in breast cancer. However, increasing evidence indicates that ferroptosis sensitivity is not solely determined by tumour‐intrinsic factors, but is dynamically regulated by the tumour microenvironment (TME), particularly through interactions among adipocytes, immune cells and iron metabolism. Main body Recent studies provide mechanistic evidence for this context dependence. Adipocyte‐derived monounsaturated fatty acids such as oleic acid suppress lipid peroxidation and increase resistance to ferroptosis induction in triple‐negative breast cancer, whereas ACSL4‐driven polyunsaturated phospholipid remodelling enhances ferroptosis susceptibility. In parallel, CD8 + T‐cell‐derived interferon‐γ promotes ferroptosis by suppressing SLC7A11‐mediated cystine uptake, while tumour‐associated macrophages buffer oxidative stress through iron sequestration and glutathione‐dependent antioxidant programs. These opposing forces indicate that ferroptosis is governed by a coordinated adipocyte–immune–iron regulatory network rather than a single pathway. Unlike previous reviews focused mainly on tumour–intrinsic mechanisms or general TME effects, this review integrates adipocyte‐derived lipid metabolism, immune‐mediated redox regulation, iron handling and spatial heterogeneity into a unified ‘ferroptosis ecosystem’ framework. Based on this concept, we propose eco‐ferrotherapy, a translational strategy aimed at simultaneously targeting tumour‐intrinsic pathways and microenvironmental buffering systems. This framework may support subtype‐specific therapeutic prioritisation, biomarker‐guided patient stratification and rational combination strategies involving immunotherapy and nanomedicine.
Conclusion
Ferroptosis in breast cancer should be understood as an ecosystem‐level vulnerability shaped by metabolic, immune and spatial factors. Defining and therapeutically targeting this ferroptosis ecosystem provides a conceptual and translational roadmap for improving precision treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng District, Beijing, China.
ORCID-Profile: Juan Sun
Förderung
- Fundamental Research Funds for the Central Universities
- Peking Union Medical College
Zitieren
APA
Sun, J., Qu, Y., Yao, R., & Zhou, Y. (2026). Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application. Clinical and Translational Medicine, 16(6). https://doi.org/10.1002/ctm2.70707
Vancouver
Sun J, Qu Y, Yao R, Zhou Y. Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application. Clinical and Translational Medicine. 2026;16(6). doi:10.1002/ctm2.70707
BibTeX
@article{Sun2026,
author = {Sun, Juan and Qu, Yang and Yao, Ru and Zhou, Yidong},
title = {Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {6},
doi = {10.1002/ctm2.70707}
}
EUVIMED